TARDIS - Photo Elicitation and Intervention
Part of paid clinical trials in Durham, North Carolina.
- Sponsor
- VA Office of Research and Development
- Study ID
- NCT06972251
- Status
- Completed
Conditions
- Diabetes Distress
- Diabetes Mellitus, Type II
- Self Management
- Type 2 Diabetes
- Veteran
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- TARDIS Photo Elicitation — BEHAVIORALUsing visual-based qualitative methods to help identify and more robustly describe DD in Veterans.
- TARDIS Intervention — BEHAVIORALDesign \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with type 2 diabetes (T2D), to promote engagement in self-management behaviors.
Study Details
Veterans with type 2 diabetes (T2D) may become overwhelmed with the self-management behaviors needed to maintain optimal health. Veterans may experience diabetes distress (DD), a concept distinct from depression, due the amount and frequency of these behaviors. Diabetes distress negatively influences the Veteran's engagement in self-management and subsequent glycosylated hemoglobin (HbA1c) levels. Previous interventions aimed at improving T2D self-management and reducing DD do not tailor T2D self-management information to a Veteran's DD, which may be one reason interventions are ineffective at reducing DD. The purpose of this study is to further understand DD by expanding on what the investigators have learned thus far in cognitive and semi-structured interviews with Veterans (see ClinicalTrials.gov identifier NCT04587336). In Aim 3a, the photo elicitation study, the Veteran would be provided with a camera and instructed to take approximately 20 photos over two weeks. The investigators would conduct two semi-structured interviews with the Veteran to discuss this experience. Visual-based qualitative methods will help us identify and more robustly describe DD in Veterans. In Aim 3b, the investigators will conduct a pilot study of a novel telemedicine intervention. The TARDIS intervention (Aim 3b) will build off data collected in Aim 3a and provide tailored coaching to Veterans with type 2 diabetes mellitus. The TARDIS intervention includes coaching, self-management information, and referrals to Veterans Health Administration (VHA) supportive services delivered via the telephone. TARDIS will augment current VHA care for patients with diabetes. All Veterans will continue to receive care from their primary clinicians during the study.
Key Dates
- Start date
- Mar 8, 2022
- Status verified
- Sep 2025
- Primary completion
- Mar 31, 2024
- Completion
- Mar 31, 2025
Study Design
- Enrollment
- 34 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Other: Aim 3a - TARDIS Photo ElicitationTo further understand Diabetes Distress (DD) by expanding on what we have learned thus far in cognitive and semi-structured interviews with Veterans. Visual-based qualitative methods will help identify and more robustly describe DD in Veterans.
- Other: Aim 3b - TARDIS InterventionDesign \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with type 2 diabetes (T2D), to promote engagement in self-management behaviors.
Primary Outcome Measure
Diabetes Distress Scale Score [ Time Frame: Baseline ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Durham VA Medical Center, Durham, NC | Durham | North Carolina | 27705-3875 | - |
Find similar trials in Durham, NC
Related Studies
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama
- Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE USRecruiting · Duke University · Charlotte, North Carolina
- Improving Appetite Self-Regulation in African American Adults With Type 2 DiabetesRecruiting · University of North Carolina, Chapel Hill · Kannapolis, North Carolina
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona